Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PT-886 by Phanes Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
PT-886 is under clinical development by Phanes Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
PT-886 by Phanes Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PT-886 is under clinical development by Phanes Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
PT-886 by Phanes Therapeutics for Gastric Cancer: Likelihood of Approval
PT-886 is under clinical development by Phanes Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
PT-199 by Phanes Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PT-199 is under clinical development by Phanes Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
PT-199 by Phanes Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
PT-199 is under clinical development by Phanes Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PT-217 by Phanes Therapeutics for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to...
PT-217 by Phanes Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
PT-217 by Phanes Therapeutics for Prostate Cancer: Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
PT-217 by Phanes Therapeutics for Neuroendocrine Cancer: Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase...